There are currently 1317 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
NCT06495125
Recruiting
This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) to an anti-PD1 treatment and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Defactinib and avutometinib belong to a class of drugs called kinase inhibitors. These drugs target kinase proteins found in tumor cells. Tumor cells need... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Efficacy and Sustainability of a Carepartner-Integrated Telerehabilitation Program for Persons With Stroke
NCT06655402
Recruiting
Stroke is a leading cause of long-term disability. Research has placed little emphasis on integrating care partners (CP) (family members) into the rehabilitation process without increasing negative care partner outcomes. The research team has developed and implemented a novel, web-based care partner-focused intervention (CARE-CITE) designed to foster problem-solving and skill building while facilitating care partner engagement during stroke survivor (SS) upper extremity practice of daily activit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Emory Rehabilitation Hospital, Atlanta, Georgia
Conditions: Stroke, Caregiver Burden
Register for Updates
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645
Recruiting
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survi... Read More
Gender:
ALL
Ages:
Between 6 years and 39 years
Trial Updated:
04/14/2025
Locations: Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
Conditions: Down Syndrome, B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia
Conditions: Metastatic Urothelial Cancer
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #100, Atlanta, Georgia
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
NCT04847453
Recruiting
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change \[translocation t(11;14)\]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: AL Amyloidosis
Register for Updates
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
NCT05417971
Recruiting
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Caitlin Guzowski, Atlanta, Georgia
Conditions: Hematologic Malignancy
Register for Updates
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491
Recruiting
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2025
Locations: Emory University at Grady, Atlanta, Georgia
Conditions: Acute Ischemic Stroke
Register for Updates
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT05548296
Recruiting
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
Register for Updates
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
NCT06075745
Recruiting
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Liver Transplant
Register for Updates
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
NCT06046248
Recruiting
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Chronic Graft Versus Host Disease
Register for Updates
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592
Recruiting
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term... Read More
Gender:
ALL
Ages:
Between 1 year and 75 years
Trial Updated:
04/11/2025
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia +1 locations
Conditions: Severe Aplastic Anemia
Register for Updates